Christine M Kulle, NP
Nurse Practitioner · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · UCSF Health Medical Foundation · 40 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Christine M Kulle’s office at (650) 701-1882 to ask if they take your plan before you enroll.
California Medical Board record
Licence C20185 · Deceased
Licence status: Deceased · since 1958 · Loyola University of Chicago Stritch School of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$7,691
Medicare paid this office $7,691 for 60 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 24 | $2,315 | $80 |
| Short return visit (20+ min) | 20 | $1,497 | $71 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 32 | $1,302 | $41 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 21 | $1,026 | $49 |
Who their Medicare patients are
60 Original Medicare patients in 2024. Average age 72 · Women 100% · Also on Medicaid 0% · Health risk score 0.62. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 52% · Cancer 20%.
The office billed $35,578, Medicare allowed $10,695 and paid $7,691; for 138 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 60 | 138 | 72 | 0.62 | $35,578 | $7,691 |
| 2023 | 59 | 151 | 72 | 0.71 | $42,722 | $10,939 |
| 2022 | 58 | 91 | 72 | 0.66 | $21,527 | $5,041 |
| 2021 | 51 | 81 | 71 | 0.60 | $15,846 | $4,093 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 21 | $2,969 | $99 |
| Short return visit (20+ min) | 14 | $1,283 | $68 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 23 | $1,115 | $48 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 25 | $1,036 | $41 |
2022: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $957 | $42 |
| Short return visit (20+ min) | 16 | $891 | $52 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $575 | $48 |
2021: 3 services
| Short return visit (20+ min) | 16 | $1,213 | $67 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 28 | $1,154 | $41 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $900 | $47 |
Drugs they prescribed that Part D paid
$27,462
Pharmacies billed $27,462 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 228) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
175 generic and 53 brand-name prescriptions · $27,462 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 11 | $5,680 | $516 |
| Estradiol (Twice Weekly) | 27 | $3,816 | $141 |
| Progesterone | 57 | $2,699 | $47 |
| Estradiol | 21 | $1,990 | $95 |
| Yuvafem | 14 | $1,813 | $130 |
See all 6 drugs
| Estring | 11 | $5,680 | $516 |
| Estradiol (Twice Weekly) | 27 | $3,816 | $141 |
| Progesterone | 57 | $2,699 | $47 |
| Estradiol | 21 | $1,990 | $95 |
| Yuvafem | 14 | $1,813 | $130 |
| Levothyroxine | 14 | $175 | $13 |
Year by year
| 2024 | 228 | 52 | 0% (0) | 23% | $27,462 |
| 2023 | 196 | 49 | 0% (0) | 27% | $28,642 |
| 2022 | 134 | 43 | 0% (0) | None | $18,389 |
| 2021 | 78 | 31 | 0% (0) | None | $9,692 |
| 2020 | 88 | 15 | 0% (0) | 18% | $5,895 |
| 2019 | 75 | 18 | 0% (0) | 21% | $3,619 |
| 2018 | 62 | 18 | 0% (0) | 27% | $3,266 |
| 2017 | 31 | 13 | 0% (0) | None | $843 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Estring | 13 | $6,933 | $533 |
| Estradiol (Twice Weekly) | 22 | $4,222 | $192 |
| Progesterone | 46 | $3,566 | $78 |
| Estradiol | 22 | $1,301 | $59 |
| Fluconazole | 11 | $73 | $7 |
2022: 2 drugs
| Estradiol (Twice Weekly) | 22 | $3,610 | $164 |
| Progesterone | 30 | $2,011 | $67 |
2021: 1 drug
| Vivelle-Dot | 15 | $2,418 | $161 |
2020: 3 drugs
| Vivelle-Dot | 12 | $1,695 | $141 |
| Progesterone | 18 | $1,259 | $70 |
| Estradiol | 11 | $1,112 | $101 |
2019: 3 drugs
| Vivelle-Dot | 13 | $1,842 | $142 |
| Progesterone | 22 | $888 | $40 |
| Alendronate | 12 | $46 | $4 |
2018: 2 drugs
| Progesterone | 13 | $506 | $39 |
| Alendronate | 11 | $20 | $2 |
2017: 1 drug
| Alendronate | 11 | $29 | $3 |
Money from drug and device companies
$419 in 2025
| 2025 | 7 | 16 | None | $419 |
| 2024 | 10 | 45 | None | $715 |
| 2023 | 14 | 54 | None | $817 |
| 2022 | 7 | 16 | None | $348 |
| 2021 | 2 | 2 | None | $36 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $217 | 6 payments
|
| Mayne Pharma Commercial | None | $52 | 3 payments
|
| Exact Sciences | Cologuard Collection Kit | $47 | 2 payments
|
| Sumitomo Pharma America | Myfembree | $34 | 2 payments
|
| Biogen | Zurzuvae | $24 | 1 payment
|
| Millicent US | Femlyv | $24 | 1 payment
|
See all 16 published payments
| Astellas Pharma US | Education · 2025-12-19 | None | $79 |
| Sumitomo Pharma America | Meals · 2025-12-16 | Myfembree | $19 |
| Organon | Meals · 2025-12-05 | Nexplanon | $21 |
| Mayne Pharma Commercial | Meals · 2025-11-11 | None | $12 |
| Astellas Pharma US | Meals · 2025-11-10 | Veozah | $34 |
| Mayne Pharma Commercial | Meals · 2025-11-07 | None | $29 |
| Exact Sciences | Meals · 2025-10-27 | None | $18 |
| Mayne Pharma Commercial | Meals · 2025-09-30 | None | $11 |
| Astellas Pharma US | Meals · 2025-09-24 | Veozah | $27 |
| Astellas Pharma US | Meals · 2025-07-29 | Veozah | $30 |
| Millicent US | Meals · 2025-05-27 | Femlyv | $24 |
| Sumitomo Pharma America | Meals · 2025-04-15 | Gemtesa | $15 |
| Astellas Pharma US | Meals · 2025-03-26 | Veozah | $26 |
| Astellas Pharma US | Meals · 2025-02-25 | Veozah | $20 |
| Exact Sciences | Meals · 2025-02-10 | Cologuard Collection Kit | $29 |
| Biogen | Meals · 2025-01-14 | Zurzuvae | $24 |
See earlier years (2024, 2023, 2022, 2021)
2024: $715
| Mayne Pharma Commercial | None | $308 | 26 payments
|
| Astellas Pharma US | Veozah | $127 | 5 payments
|
| Organon | Nexplanon | $65 | 3 payments
|
| Lilly USA | Zepbound | $56 | 3 payments
|
| Biogen | Zurzuvae | $46 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $44 | 2 payments
|
| Evofem Biosciences | None | $23 | 1 payment
|
| Novo Nordisk | Wegovy | $19 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $14 | 1 payment
|
| Bausch Health US | Aplenzin | $13 | 1 payment
|
2023: $817
| Mayne Pharma Commercial | None | $421 | 35 payments
|
| Exact Sciences | Cologuard Collection Kit | $131 | 6 payments
|
| Novo Nordisk | Saxenda | $37 | 2 payments
|
| Pacira Pharmaceuticals | Exparel | $29 | 1 payment
|
| Abbvie | Ubrelvy | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kyleena | $24 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $23 | 1 payment
|
| Shield Therapeutics | Accrufer | $22 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $21 | 1 payment
|
| Ethicon US | Ethicon | $20 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $17 | 1 payment
|
| Astellas Pharma US | Veozah | $17 | 1 payment
|
| Bausch Health US | Aplenzin | $16 | 1 payment
|
| CooperSurgical | Paragard T 380a | $14 | 1 payment
|
2022: $348
| Abbvie | Lo Loestrin Fe | $96 | 4 payments
|
| TherapeuticsMD | Annovera | $75 | 4 payments
|
| Mayne Pharma | None | $47 | 2 payments
|
| ASCEND Therapeutics US | Estrogel | $40 | 2 payments
|
| Myovant Sciences | Myfembree | $39 | 2 payments
|
| Organon | Nexplanon | $27 | 1 payment
|
| Bausch Health US | Aplenzin | $24 | 1 payment
|
2021: $36
| AbbVie | Lo Loestrin Fe | $28 | 1 payment
|
| Organon | Nexplanon | $9 | 1 payment
|
Professional record
- NPI
- 1306154976
- Licence
- CA 1200, CA 20185California C20185: Deceased
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Advanced practice midwife (367A00000X)
- Mailing address
- 476 E Campbell Ave, Campbell, CA, 95008
- NPI first listed
- 2010-09-17
- NPI last updated
- 2020-11-30
- NPI record certified
- 2020-11-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 298 San Antonio Rd Ste 100, Mountain View, CA, 94040 · 12 N White Rd Ste 1, San Jose, CA, 95127 · 1671 the Alameda Ste 101, San Jose, CA, 95126 · 33523 Western Ave, Union City, CA, 94587